Study at a glance
How does the liver start converting vitamin D?
This review examines CYP2R1, an enzyme that helps the liver convert vitamin D into 25-hydroxyvitamin D, the form measured in most vitamin D blood tests. This is an earlier step than making the main active hormone. The review combines rare human genetic disorders, mouse experiments, human tissue samples and laboratory liver-cell studies.
What shows that this liver enzyme matters?
A rare inherited CYP2R1 change was linked to rickets and very low 25-hydroxyvitamin D. Tests of the altered protein showed reduced conversion. Later family studies extended this evidence, but selected families cannot show how often enzyme defects explain ordinary low blood results. Mice lacking CYP2R1 still produced some 25-hydroxyvitamin D, showing that it is important but not the only possible route.
Do changes in the body always reduce vitamin D conversion?
No. Some high-fat-diet mouse experiments found lower liver enzyme amounts and conversion activity. Human observations were more limited: samples after weight-loss surgery came from fat, not liver, and could not separate surgery from weight loss. A human liver-cell model showed changes that were not fully reproduced in patient liver data. In one diabetic mouse model, lower CYP2R1 gene activity occurred alongside increased overall conversion, possibly through other enzymes.
Can a low vitamin D result diagnose poor liver conversion?
Gene activity, enzyme amount, conversion measured in a laboratory and a blood vitamin D result are different measurements. They need not all move together. The evidence does not show that every metabolic disturbance reduces CYP2R1 or that a low blood result diagnoses poor liver conversion. It also does not establish a personal vitamin D target or which preparation an individual should take.
Read the full article below ↓The liver helps convert vitamin D into 25-hydroxyvitamin D, usually shortened to 25(OH)D, the metabolite measured in most vitamin D blood tests. CYP2R1 is an important enzyme in that conversion, but its abundance and contribution cannot be read directly from a blood result. This review examines genetic, animal and human-tissue evidence within the wider subject of Vitamin D and Liver Function. For the shorter version, see Hepatic CYP2R1 and Vitamin D Conversion: Study Summary.
The question is conversion capacity, not simply vitamin D intake
Hydroxylation means adding a hydroxyl group to a molecule. CYP2R1 performs a 25-hydroxylation step, producing a circulating precursor that can subsequently undergo a different conversion to calcitriol, or 1,25-dihydroxyvitamin D. The distinction matters: making 25(OH)D and making the principal active hormone are related processes, but they are not the same measurement. The general sequence is explained in Vitamin D Activation.
The specific question here is whether the first conversion behaves as an unchanging processing step. A convincing answer requires more than finding low 25(OH)D in people with a particular condition. Researchers must distinguish the supply of the starting molecule, the machinery that converts it, the resulting product and the physiological response. These quantities can move together, but a study must show which connections it actually measured.
The evidence below therefore has several jobs. Human genetics tests whether a damaged enzyme can matter biologically. Removing a gene in mice tests its contribution and possible compensation. Dietary experiments investigate regulation. Human tissue sampling tests a narrower question about expression in the sampled tissue. This is a focused narrative review of those experiments, not a systematic review or an estimate of how commonly impaired conversion occurs in the general population.
Human genetics identifies a biologically important enzyme
Cheng and colleagues examined a Nigerian patient with rickets and very low 25(OH)D: 10 to 12 nmol/L. Circulating calcitriol was within the reported reference range. Sequencing identified an L99P substitution in both copies of CYP2R1; the change was absent from 50 control individuals. In transfected human cells, the altered protein lost detectable vitamin D3 conversion activity under the tested conditions, while retaining some activity with vitamin D2 at high substrate concentrations.
The important inference is the connection between a molecular defect and an experimentally demonstrated loss of function. This is stronger evidence for the enzyme’s importance than a simple correlation between a gene marker and a blood concentration. However, one rare inherited disorder does not measure how frequently conversion limits vitamin D status in ordinary adults. Its normal calcitriol result also illustrates why one metabolite cannot substitute for a complete account of the pathway.
A later clinical series by Bakhamis and colleagues included 27 affected individuals from nine Saudi Arabian families. Eighteen carried an identified CYP2R1 variant in both gene copies and nine in one copy. Recruitment focused on persistent low 25(OH)D despite substantial treatment or dependence on treatment, with affected relatives also investigated. Molecular testing and clinical assessment extended the human evidence beyond the original patient.
This series supports variable clinical expression within an inherited conversion disorder, but its selection process matters. Twenty-seven family members are not 27 unrelated samples of the general population. Recruitment enriched the cohort for unusual vitamin D responses, and inclusion required an identified variant. Consequently, the proportion with a mutation cannot estimate the proportion of everyday low blood results caused by CYP2R1 defects. Treatment observations in this selected group also cannot establish a regimen for people whose low result has a different cause.
A useful reading question is whether a study examines the enzyme itself or merely something associated with it. In Cheng’s experiment, researchers tested the altered protein. That is different from assuming that every person with low 25(OH)D carries a damaging mutation. The broader biochemical sequence remains the subject of the stepwise conversion of vitamin D3 to its active hormone.
Deleting CYP2R1 reveals both its contribution and residual conversion
Zhu and colleagues generated mice lacking Cyp2r1, alone or together with Cyp27a1. At ten weeks, mass-spectrometry measurements of 25(OH)D3 were 16.8 ± 1.6 ng/mL in wild-type mice, 6.8 ± 1.2 after Cyp2r1 deletion and 10.9 ± 1.7 after both deletions. The metabolite remained measurable, and liver preparations retained conversion activity. The authors also found that the radioimmunoassay produced higher values than chromatographic methods because it detected additional metabolites.
These results support “major contributor” rather than “only possible route”. They also show why the analytical method belongs in the interpretation: the absolute size of a difference can depend on what the assay detects. Residual production does not identify the alternative enzyme, and preserved hormone concentrations in a mouse do not establish an acceptable blood threshold for humans. The experiment answers a pathway question, not a clinical target-setting question.
The obesity experiment tests conversion more directly
Roizen and colleagues compared female mice fed high-fat or control diets from weaning, assessing several ages between six and 24 weeks. They measured hepatic gene expression, circulating metabolites and conversion in liver preparations. At 13 weeks, the ex vivo assay produced 1.8 ± 0.4 versus 0.6 ± 0.2 ng/mL per gram of liver in lean and obese groups, respectively, with five mice per group and P<0.05. The assay used vitamin D2 as substrate. Circulating vitamin D3 was similar between groups, while the product-to-substrate ratio was lower with the high-fat diet.
The combination is informative because it goes beyond a single low blood result. The tissue assay provides a separate test of conversion under controlled laboratory conditions. Nevertheless, diet composition, energy intake and weight gain changed together; the comparison does not isolate body fat from every dietary effect. A liver preparation also lacks the normal circulation and tissue exchanges. It measures an experimental capacity, not the daily amount converted throughout an intact human body.
The reported relation between gene expression and the circulating ratio is a model-specific association. It cannot be converted into a percentage of human vitamin D deficiency explained by CYP2R1. Nor does the observation establish which upstream dietary or inflammatory signal caused the expression change. Those questions need different experiments. Related organ-to-organ activation evidence is considered in the hepatic: renal vitamin D3 activation review.
A second obesity study separates mouse liver from human fat
Elkhwanky and colleagues studied a 16-week high-fat diet in male and female mice. Final groups contained seven high-fat-fed mice of each sex, four male controls and five female controls; one male control was removed for welfare reasons. Estimated vitamin D intake was similar between diets. Hepatic CYP2R1 protein fell by 63% in males and 69% in females, alongside lower circulating 25(OH)D. Allocation was random, but investigators were not blinded to handling or endpoint measurements.
The human component involved four women, aged 30 to 43, sampled before and 11 to 19 months after gastric bypass. CYP2R1 messenger RNA rose approximately 1.5-fold in subcutaneous fat. These were adipose biopsies, not liver biopsies. Surgery, weight loss and other postoperative changes were inseparable in this small uncontrolled comparison.
It is tempting to join those two components into a single story: obesity suppresses the human liver enzyme and weight loss restores it. That step would exceed the design. The human samples demonstrate a change in a different tissue, and messenger RNA is an expression signal rather than a direct assay of conversion. The correct synthesis preserves the gap between the mouse liver evidence and the human observation instead of filling it with an assumption.
Human-cell evidence adds a further comparison
Hammour and colleagues reported a three-dimensional human liver-cell model in 2026. Seven-day fatty-acid exposure reduced CYP2R1 and CYP27A1 expression and 25(OH)D3 output in laboratory spheroids. The conversion assay used a four-hour, 20 μM vitamin D exposure and an immunoassay; experiments had three independent repetitions. This is controlled human-cell evidence, but it does not measure conversion inside a patient.
Crucially, their separate analysis of liver RNA data from eight people with metabolic dysfunction-associated steatotic liver disease, or MASLD, and seven controls found reduced CYP27A1 but unchanged CYP2R1. The patient expression data therefore did not reproduce both laboratory changes. That discrepancy limits a universal CYP2R1-suppression explanation. Neither the cell model nor the patient dataset measures how much one enzyme contributes to an individual’s circulating concentration.
Metabolic regulation does not have one universal outcome
Aatsinki and colleagues investigated fasting and diabetic mouse models, with experiments manipulating transcriptional regulators in hepatocytes. Their findings implicated PGC-1α/ERRα and glucocorticoid-related regulation in CYP2R1 repression. This supplies a plausible route by which metabolic signals can affect expression; it does not establish a universal response to fasting or diabetes in humans.
The distinction between making a pathway active and proving it necessary is useful here. Increasing PGC-1α in hepatocytes reduced CYP2R1 expression, but removing PGC-1α did not prevent fasting-associated repression in the liver. Blocking glucocorticoid signalling only partly prevented the response. These findings favour overlapping regulatory influences. They do not support a model in which one transcription factor completely explains every reduction in CYP2R1.
A later experiment from Elkhwanky and colleagues provides a useful counterexample. In male mice with streptozotocin-induced insulin-deficient diabetes, hepatic Cyp2r1 expression decreased, yet circulating 25(OH)D increased at four and eight weeks and was not significantly different at 13 weeks. Liver microsomal 25-hydroxylase activity increased. The authors proposed compensation by other enzymes, but did not establish the responsible enzyme. Insulin treatment corrected blood glucose without restoring Cyp2r1 expression.
This counterexample changes the strength of the general claim. Reduced expression can accompany reduced conversion in one model without guaranteeing the same net result in another. The amount of transcript, functional protein, total conversion capacity and circulating product must each be kept identifiable. This is why vitamin D metabolism at the cellular level cannot be reduced to a single gene-expression result.
What the measurements can and cannot distinguish
A gene-expression assay asks how much messenger RNA is present relative to its reference. A protein assay asks about protein abundance. An activity assay asks how much product forms under specified conditions. A blood assay asks how much metabolite is circulating at a particular time. Agreement among these measurements strengthens a mechanistic explanation, but none becomes interchangeable with the others merely because all concern vitamin D.
A product-to-substrate ratio adds information, but it is not automatically a conversion rate. A ratio can change when its numerator changes, its denominator changes, or both change. Measurements taken at one time do not reveal how quickly either pool is being replenished or removed. That is why pairing a circulating ratio with a separate tissue-activity experiment is more informative than presenting the ratio alone as proof of enzyme function.
Consider a hypothetical study that finds a lower blood concentration but never samples the liver. It cannot distinguish reduced synthesis from altered distribution using that result alone. Conversely, finding less enzyme protein without measuring activity cannot show how much conversion changed. The most useful evidence is therefore the chain connecting independent measurements, together with any points where the chain breaks. The diabetes counterexample makes that requirement practical rather than theoretical.
Carrier measurements add another dimension. Total concentration includes material associated with blood proteins, so interpretation also needs the background described in Vitamin D Transport Proteins and Vitamin D Binding Protein Explained. These connections do not turn the present conversion studies into studies of carrier synthesis. They identify another variable that would need measurement before assigning a low result to one hepatic mechanism.
Implications and unresolved questions
The evidence supports a substantial role for CYP2R1 in vitamin D conversion and demonstrates regulation under experimental metabolic conditions. Whole-animal obesity experiments, human-cell models, patient tissue data and inherited disorders contribute different pieces. Their results do not support assuming that every metabolic disturbance suppresses CYP2R1 or that lower expression always produces less circulating 25(OH)D.
A more decisive human study would connect carefully characterised exposure, liver-specific measurements and metabolite kinetics while addressing changes in carriers, distribution and clearance. Repeated observations could help establish timing, but would still need to distinguish what changed together from what caused the change. Comparing intervention groups would answer a further question about reversibility; it would not be replaced by comparing unrelated people with different body weights.
For readers, the resulting conclusion is specific: 25(OH)D is a product of a biological pathway, so its concentration cannot be interpreted as a direct readout of intake or CYP2R1 activity. These experiments improve the explanation of that pathway. They do not diagnose an individual’s liver conversion capacity, establish a personal blood target or determine which vitamin D preparation someone should take.
Scientific sources
Cheng JB et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proceedings of the National Academy of Sciences. 2004;101(20):7711 to 7715. DOI: 10.1073/pnas.0402490101.
Bakhamis S et al. 25-Hydroxylase vitamin D deficiency in 27 Saudi Arabian subjects: a clinical and molecular report on CYP2R1 mutations. Endocrine Connections. 2021;10(7):767 to 775. DOI: 10.1530/EC-21-0102.
Zhu JG et al. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proceedings of the National Academy of Sciences. 2013;110(39):15650 to 15655. DOI: 10.1073/pnas.1315006110.
Roizen JD et al. Obesity Decreases Hepatic 25-Hydroxylase Activity Causing Low Serum 25-Hydroxyvitamin D. Journal of Bone and Mineral Research. 2019;34(6):1068 to 1073. DOI: 10.1002/jbmr.3686.
Elkhwanky MS et al. Obesity Represses CYP2R1, the Vitamin D 25-Hydroxylase, in the Liver and Extrahepatic Tissues. JBMR Plus. 2020;4(11):e10397. DOI: 10.1002/jbm4.10397.
Hammour MM et al. Free Fatty acid-induced disruption of hepatic vitamin D metabolism impairs bone homeostasis in an in vitro 3D human liver: bone model. Archives of Toxicology. 2026;100:4151 to 4169. DOI: 10.1007/s00204-026-04431-x.
Aatsinki SM et al. Fasting-Induced Transcription Factors Repress Vitamin D Bioactivation, a Mechanism for Vitamin D Deficiency in Diabetes. Diabetes. 2019;68(5):918 to 931. DOI: 10.2337/db18-1050.
Elkhwanky MS, Kummu O, Hakkola J. Streptozotocin-induced Diabetes Represses Hepatic CYP2R1 Expression but Induces Vitamin D 25-Hydroxylation in Male Mice. Endocrinology. 2022;163(7):bqac060. DOI: 10.1210/endocr/bqac060.
Related reading
Anthropometric, biochemical and clinical assessment of malnutrition among Egyptian children with chronic liver diseases: a single institutional cross-sectional study
We aimed to assess the nutritional status of children with CLD and to correlate the anthropometric indices with the severity of liver disease, liver function tests, insulin growth factor-1 (IGF-1) and 25-hydroxy vitamin D (25: OH D).
Original paper ↗Read more →Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy
LSMs were re-evaluated at 48 weeks.
Original paper ↗Read more →Dietary Tannic Acid Improves Hepatic Health and Capacity to Deal with Temperature Fluctuation in the Chinese Soft-Shelled Turtle (Pelodiscus sinensis)
Herein, we evaluated the roles of dietary tannic acid in regulating liver health under temperature fluctuations.
Original paper ↗Read more →Disrupted Vitamin D Metabolism in Hepatocellular Carcinoma: Free and Bioavailable 25(OH)D as Novel Biomarkers of Hepatic Reserve and Clinical Risk
Correlations with Child: Pugh score, Barcelona Clinic Liver Cancer (BCLC) stage, and disease aetiology were evaluated.
Original paper ↗Read more →Exploring the association between serum vitamins and CAP-defined hepatic steatosis in lean and non-lean adults with NAFLD: A cross-sectional study
This study evaluated associations between serum levels of vitamins A, C, D, and E and the degree of CAP-defined hepatic steatosis in lean and non-lean adults.
Original paper ↗Read more →Functional evolution of the vitamin D and pregnane X receptors
In this study, the ligand selectivities of VDRs were compared in detail across a range of vertebrate species and compared with those of the Ciona VDR/PXR.
Original paper ↗Read more →HBV activates hepatic stellate cells through RUNX2/ITGBL1 axis
We examined the relationship between RUNX2 and ITGBL1 in both in vitro hepatocyte models and an in vivo HBV mouse model.
Original paper ↗Read more →Inverted U-shaped relationships between bone mineral density and VCTE-quantified degree of hepatic steatosis in adolescents: Evidence from the NHANES
There may be inaccuracies in hepatic steatosis in past research assessing the relationship between bone metabolism and liver steatosis.
Original paper ↗Read more →Low Serum 25-Hydroxy Vitamin D (25-OHD) and Hepatic Encephalopathy in HCV-Related Liver Cirrhosis
Aim of the Study.
Original paper ↗Read more →MASLD in the oldest-old: lack of association with cognition or functional autonomy and poor predictive utility of the hepatic steatosis index
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition increasingly recognized in aging populations.
Original paper ↗Read more →Maternal Vitamin D Deficiency During Pregnancy Alters Hepatic Metabolism in Adult Female Offspring Without Overt Metabolic Dysfunction
This study aimed to comprehensively assess hepatic metabolic profiles in female offspring exposed to maternal VDD during gestation.
Original paper ↗Read more →New Variants of the Cytochrome P450 2R1 (CYP2R1) Gene in Individuals with Severe Vitamin D-Activating Enzyme 25(OH)D Deficiency
Background: Vitamin D is a fat-soluble cholesterol derivative found in two forms, vitamin D2, and vitamin D3.
Original paper ↗Read more →Periostin involved in the activated hepatic stellate cells-induced progression of residual hepatocellular carcinoma after sublethal heat treatment: its role and potential for therapeutic inhibition
Here, we investigated whether activated hepatic stellate cells (HSCs) would accelerate the progression of residual HCC after sublethal heat treatment, and thus sought to identify the potential targets.
Original paper ↗Read more →Protective Effect of Vitamin D against Hepatic Molecular Apoptosis Caused by a High-Fat Diet in Rats
We aimed in this study to investigate the protective effects of VitD on hepatic molecular apoptotic changes in response to an HFD in rats.
Original paper ↗Read more →Streptozotocin-induced Diabetes Represses Hepatic CYP2R1 Expression but Induces Vitamin D 25-Hydroxylation in Male Mice
Vitamin D deficiency [ie, low plasma 25-hydroxyvitamin D (25-OH-D)] associates with the prevalence of metabolic diseases including type 1 diabetes; however, the molecular mechanisms are incompletely understood.
Original paper ↗Read more →The clinical and biochemical effectiveness and safety of cholic acid treatment for bile acid synthesis defects: a systematic review
Bile acid synthesis defects (BASDs) can be severely disabling involving the liver and nervous system, potentially due to elevated levels of toxic C27-bile acid intermediates.
Original paper ↗Read more →The Effects of Vitamin D Supplementation on Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Children and Adolescents with Vitamin D Deficiency and Either Type 1 or Type 2 Diabetes Mellitus
The effects of vitamin D supplementation on mild hepatic dysfunction and glycemic control are unclear in children and adolescents with either type 1 (T1D) or type 2 diabetes (T2D).
Original paper ↗Read more →The Role of Vitamin D Deficiency in Hepatic Encephalopathy: A Review of Pathophysiology, Clinical Outcomes, and Therapeutic Potential
Hepatic encephalopathy (HE) is a neuropsychiatric condition frequently associated with cirrhosis and portosystemic shunting (PSS).
Original paper ↗Read more →Vitamin D Ameliorates the Hepatic Oxidative Damage and Fibrotic Effect Caused by Thioacetamide in Rats
Vitamin D3 (VD3) is a sunshine hormone that regulates cellular proliferation, differentiation, apoptosis, and angiogenesis related to liver parenchyma.
Original paper ↗Read more →Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: A randomized, double-blind, placebo-controlled study
Fifty-four CHC patients with VD deficiency were randomized into two groups, a VD group (n = 29) and a placebo group (n = 29).
Original paper ↗Read more →Obesity Represses CYP2R1, the Vitamin D 25‐Hydroxylase, in the Liver and Extrahepatic Tissues
Low plasma level of 25‐hydroxyvitamin D (25‐OH‐D), namely vitamin D deficiency, is associated with obesity and weight loss improves 25‐OH‐D status.
Original paper ↗Read more →Original sources
Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase
Published in Proceedings of the National Academy of Sciences (2004).
Publication details
Cheng JB et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proceedings of the National Academy of Sciences. 2004;101(20):7711 to 7715. DOI: 10.1073/pnas.0402490101.
25-Hydroxylase vitamin D deficiency in 27 Saudi Arabian subjects: a clinical and molecular report on CYP2R1 mutations
Published in Endocrine Connections (2021).
Publication details
Bakhamis S et al. 25-Hydroxylase vitamin D deficiency in 27 Saudi Arabian subjects: a clinical and molecular report on CYP2R1 mutations. Endocrine Connections. 2021;10(7):767 to 775. DOI: 10.1530/EC-21-0102.
CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo
Published in Proceedings of the National Academy of Sciences (2013).
Publication details
Zhu JG et al. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proceedings of the National Academy of Sciences. 2013;110(39):15650 to 15655. DOI: 10.1073/pnas.1315006110.
Obesity Decreases Hepatic 25-Hydroxylase Activity Causing Low Serum 25-Hydroxyvitamin D
Published in Journal of Bone and Mineral Research (2019).
Publication details
Roizen JD et al. Obesity Decreases Hepatic 25-Hydroxylase Activity Causing Low Serum 25-Hydroxyvitamin D. Journal of Bone and Mineral Research. 2019;34(6):1068 to 1073. DOI: 10.1002/jbmr.3686.
Obesity Represses CYP2R1, the Vitamin D 25‐Hydroxylase, in the Liver and Extrahepatic Tissues
Low plasma level of 25‐hydroxyvitamin D (25‐OH‐D), namely vitamin D deficiency, is associated with obesity and weight loss improves 25‐OH‐D status.
Publication details
Elkhwanky MS et al. Obesity Represses CYP2R1, the Vitamin D 25-Hydroxylase, in the Liver and Extrahepatic Tissues. JBMR Plus. 2020;4(11):e10397. DOI: 10.1002/jbm4.10397.
Free Fatty acid-induced disruption of hepatic vitamin D metabolism impairs bone homeostasis in an in vitro 3D human liver–bone model
Published in Archives of Toxicology (2026).
Publication details
Hammour MM et al. Free Fatty acid-induced disruption of hepatic vitamin D metabolism impairs bone homeostasis in an in vitro 3D human liver: bone model. Archives of Toxicology. 2026;100:4151 to 4169. DOI: 10.1007/s00204-026-04431-x.
Fasting-Induced Transcription Factors Repress Vitamin D Bioactivation, a Mechanism for Vitamin D Deficiency in Diabetes
Published in Diabetes (2019).
Publication details
Aatsinki SM et al. Fasting-Induced Transcription Factors Repress Vitamin D Bioactivation, a Mechanism for Vitamin D Deficiency in Diabetes. Diabetes. 2019;68(5):918 to 931. DOI: 10.2337/db18-1050.
Streptozotocin-induced Diabetes Represses Hepatic CYP2R1 Expression but Induces Vitamin D 25-Hydroxylation in Male Mice
Vitamin D deficiency [ie, low plasma 25-hydroxyvitamin D (25-OH-D)] associates with the prevalence of metabolic diseases including type 1 diabetes; however, the molecular mechanisms are incompletely understood.
Publication details
Elkhwanky MS, Kummu O, Hakkola J. Streptozotocin-induced Diabetes Represses Hepatic CYP2R1 Expression but Induces Vitamin D 25-Hydroxylation in Male Mice. Endocrinology. 2022;163(7):bqac060. DOI: 10.1210/endocr/bqac060.